Ojeda-Cervantes M, Galindo-Fraga A, Morales-Buenrostro LE

Language: Spanish
References: 27
Page: 25-30
PDF size: 138.65 Kb.

ABSTRACT

Tuberculosis remains a public health problem in our country and the risk for developing active tuberculosis in patients with chronic kidney disease is 6 to 25 times higher when compared with the general population and increases to 37 times more in kidney transplant recipients. Today, tuberculin test is as screening test valid for tuberculosis in potential kidney transplant recipients, however, it is well known that patients with chronic kidney disease and renal transplant recipients have alterations in cellular immunity, so this test may be less sensitive in this particular population. In this review we will discuss the different screening tools for detecting latent tuberculosis from tuberculin test to the interferon release assays as novel diagnostic tools for tuberculosis screening.

REFERENCES

1. World Health Organization, Global Tuberculosis Control. Epidemiology, Strategy, Financing, WHO/HTM/TB/2009.411, Ginebra, Switzerland, 2009.

2. Nájera-Ortiz JC, Sánchez-Pérez HJ, Ochoa Díaz-López-H, Leal-Fernández G, Navarro-Giné A. The poor survival among pulmonary tuberculosis patients in Chiapas, Mexico: The case of Los Altos Region. Tuberc Res Treat 2012; 2012: 708423.

3. Iseki K. Metabolic syndrome and chronic kidney disease: a Japanese perspective on a worldwide problem. J Nephrol 2008; 21: 305-12.

4. Almaguer M, Herrera R, Alfonso J, Magrans C, Mañalich R, Martínez A. Primary health care strategies for the prevention of end-stage renal disease in Cuba. Kidney Int Suppl 2005; (97): S4-10.

5. Mazzuchi N, Schwedt E, Solá L, González C, Ferreiro A. Risk factors and prevention of end stage renal disease in Uruguay. Ren Fail 2006; 28: 617-25.

6. Franco-Marina F, Tirado-Gómez LL, Venado-Estrada A et al. Una estimación indirecta de las desigualdades actuales y futuras en la frecuencia de la enfermedad renal crónica terminal en México. Salud Publica Mex 2011; 53 supl 4: s506-15.

7. Wauters A, Peetermans WE, Van den Brande P, De Moor B, Evenepoel P, Keuleers H et al. The value of tuberculin skin testing in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 433-8.

8. Passalent L, Khan K, Richardson R, Wang J, Dedier H, Gardam M. Detecting latent tuberculosis infection in hemodialysis patients: a head-to-head comparison of the T-SPOT.TB test, tuberculin skin test, and an expert physician panel. Clin J Am Soc Nephrol 2007; 2: 68-73.

9. Abdelrahman M, Sinha AK, Karkar A. Tuberculosis in end-stage renal disease patients on hemodialysis. Hemodial Int 2006; 10: 360-4.

10. Sen N, Turunc T, Karatasli M, Sezer S, Demiroglu YZ, Oner Eyuboglu F. Tuberculosis in patients with end-stage renal disease undergoing dialysis in an endemic region of Turkey. Transplant Proc 2008; 40: 81-4.

11. Dervisoglu E, Yilmaz A, Sengul E. The spectrum of tuberculosis in dialysis patients. Scand J Infect Dis 2006; 38: 1040-4.

12. Currie AC, Knight SR, Morris PJ. Tuberculosis in renal transplant recipients: the evidence for prophylaxis. Transplantation 2010; 90: 695-704.

13. Muñoz P, Rodríguez C, Bouza E. Mycobacterium tuberculosis infection in recipients of solid organ transplants. Clin Infect Dis 2005; 40: 581-7.

14. Melchor JL, Gracida C, Ibarra A. Increased frequency of tuberculosis in Mexican renal transplant recipients: a single-center experience. Transplant Proc 2002; 34: 78-9.

15. British Thoracic Society Standards of Care Committee and Joint Tuberculosis Committee, Milburn H, Ashman N, Davies P et al. Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease. Thorax 2010; 65: 557-70.

16. Shankar MS, Aravindan AN, Sohal PM et al. The prevalence of tuberculin sensitivity and anergy in chronic renal failure in an endemic area: tuberculin test and the risk of post-transplant tuberculosis. Nephrol Dial Transplant 2005; 20: 2720-4.

17. Edwards PQ, Edwads LB. Story of the tuberculin test from an epidemiologic viewpoint. Am Rev Respir Dis 1960; 81(1)Pt 2: 1-47.

18. Richeldi L. An update on the diagnosis of tuberculosis infection. Am J Respir Crit Care Med 2006; 174: 736-42.

19. Jasmer RM, Nahid P, Hopewell PC. Clinical practice. Latent tuberculosis infection. N Engl J Med 2002; 347: 1860-6.

20. Andersen P, Munk ME, Pollock JM, Doherty TM. Specific immune-based diagnosis of tuberculosis. Lancet 2000; 356: 1099-104.

21. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. Am J Respir Crit Care Med 2000; 161: 1376-95.

22. Huebner RE, Schein MF, Bass JB Jr. The tuberculin skin test. Clin Infect Dis 1993; 17: 968-75.

23. Mahairas GG, Sabo PJ, Hickey MJ, Singh DC, Stover CK. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J Bacteriol 1996; 178: 1274-82.

24. Mazurek GH, Villarino ME. Guidelines for using the QuantiFERON-TB test for diagnosing latent Mycobacterium tuberculosis infection. Centers for Disease Control and Prevention. MMWR Recomm Rep 2003; 52: 15-8.

25. Mazurek GH, Jereb J, Lobue P, Iademarco MF, Metchock B, Vernon A. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 2005; 54: 49-55.

26. Connell TG, Rangaka MX, Curtis N, Wilkinson RJ. QuantiFERON-TB Gold: state of the art for the diagnosis of tuberculosis infection? Expert Rev Mol Diagn 2006; 6: 663-77.

27. Kim SH, Lee So, Park JB, Park IA, Park SJ. A prospective longitudinal study evaluating the usefulness of a T-cell based assay for latent tuberculosis infection in kidney transplant recipients. Am J Transplant 2011; 11: 1927-35.